Bayer/Monsanto (M.8084) [Archived]
Bayer/Monsanto (M.8084) [Archived]

The following Competition practice note provides comprehensive and up to date legal information covering:

  • Bayer/Monsanto (M.8084) [Archived]
  • Case facts
  • Timeline
  • Commentary
  • Related cases


ARCHIVED–this archived case hub reflects the position at the date of the decision of 21 March 2018; it is no longer maintained.

See further: timeline, commentary and related cases.

Case facts

OutlineEuropean Commission merger investigation into the proposed acquisition of Monsanto by Bayer (Case M.8084). The transaction involves horizontal overlaps in markets for the supply of ‘pesticides’ (in particular, non-selective herbicides), the supply and licensing of ‘vegetable seeds’ and the supply of ‘traits’. The proposed transaction would result in the largest portfolio of pesticides products and the strongest global market positions in seeds and traits—making the combined entity the largest integrated company in the industry.

Latest developmentsOn 21 March 2018, the Commission conditionally approved the transaction, subject to commitments.

In terms of commitments, the Commission has accepted a substantial package of divestments to address concerns in relation to overlaps in seeds, pesticides and digital agriculture markets.

PartiesBayer Aktiengesellschaft (Bayer) is a diversified German company active in the development and supply of pharmaceuticals, consumer health, agriculture (Bayer Crop Science) and animal health company. The scrutinised transaction concerns principally the Bayer Crop Science division, a division which operates three business segments: (i) Crop Protection; (ii) Seeds and Traits; and (iii) Environmental Science. Bayer is also active in developing digital agriculture technologies.

Monsanto Corporation (Monsanto), a US based agrochemical and seeds company, produces

Popular documents